Diabetes Mellitus Type I, Diabetes Mellitus Type II
Conditions
Brief summary
This is a multi-center, non-randomized, and interventional study in which subjects will use the Integrated sensor and infusion set with MiniLink Transmitter and the Medtronic Paradigm® VEO™ insulin pump (Sensor augmented pump) for 15 days. The purpose of this study is to collect performance data on the Integrated sensor and infusion set for approximately 15 days, with the intention for each subject to wear 5 sets for 3 days each.
Interventions
Sponsors
Medtronic Diabetes R&D Denmark
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject is 18 years of age or older at time of screening * Subject has a clinical diagnosis of insulin requiring diabetes, as determined by investigator. * Subject is currently using a Medtronic Paradigm Sensor Augmented insulin pump and has been so for a minimum of 3 months at time of enrollment. * Subject has Continuous Glucose Monitoring experience (min 30% of CGM use within the month prior to enrollment). * Subject has an average of 3 SMBG per day (verified via CareLink) during the month prior to enrollment. * Subject is willing to wear the study devices for the duration of the study * Subject is willing to perform frequent (min 7 per day) SMBGs during study device wear * Subject is willing to keep a short diary during the device wear.
Exclusion criteria
* Female subject is pregnant, per urine pregnancy test performed at time of enrollment in women of child bearing age. * Female subject plans to become pregnant during the course of the study. * Subject is unable to tolerate tape adhesive in the area of the placement of the study device. * Subject has any unresolved adverse skin condition in the area of the placement of the study device (e.g. psoriasis, rash, Staphylococcus infection). * The subject is not deemed to be an appropriate candidate for the study by the investigator for any reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Accuracy endpoint | 5 months | Agreement Rate (% within 20%) using VEO Pump |
| Safety endpoint | 5 months | Descriptive summary of SAE, Adverse events and Device complaints |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Accuracy endpoint | 5 months | Agreement Rate (% within 20%) using re-analyzed Guardian® REAL-Time and Paradigm® REAL-Time algorithm data |
Other
| Measure | Time frame | Description |
|---|---|---|
| Accuracy endpoint | 5 months | MARD(%), BIAS(mg/dl), MAD(mg/dl) during study |
Countries
Denmark
Contacts
Primary ContactUlrik Pedersen-Bjergaard, MD
Outcome results
None listed